Placeholder Banner

Startups

BIO recognizes the unique needs of emerging companies. From advocating for pro-innovation tax policies to encouraging an economic and policy environment to foster investment, we focus on critical issues affecting smaller companies and build programs to enhance their development.

Priorities
Finance & Tax
  • Improving market quality for small public companies, like working with Nasdaq to advocate for increased transparency around short selling positions and advocating for SEC oversight of proxy advisory firms.
  • Advocating for tax code reforms that incentivize investment in pre-revenue innovators, including the Jobs Act and Sarbanes-Oxley (SOX) Section 404(b).
  • Engaging the Committee on Foreign Investment in the U.S. (CFIUS) in it's rulemaking process to avoid an undue impact on the biotechnology sector's ability to enter into global research partnerships and attract foreign investments.
Washington DC Capitol Dome
BIO2020_ExhibitorBoothPartnering-2
BIO One-on-One Partnering

BIO recognizes the need for capital and collaboration faced by startups.  Therefore we host more than a dozen events throughout the year to help small biotechs connect with potential investors, licensors, and partners. BIO members receive discounts on registration, presentation, and exhibition fees at BIO events.

Get Involved!

Our members drive our advocacy. Join a BIO committee to help shape our policy work and stay informed.

Hear from BIO Members
Dr. Barbara Weber, CEO Tango Therapeutics
Dr. Barbara Weber, CEO Tango Therapeutics
CFIUS Hub

Explore webinars, BIO panels, comments, and more on this members only site.

BIO CEO & Investor Digital Conference

Join us for three days of productive partnering and interactive sessions. 

What’s driving record breaking investment in biotech?

Learn how the private biotech sector has racked up record-breaking investment.

MB
Member Spotlight - Marc Belsky

“Our ability to affect change through our involvement on the Finance and Tax Committee at BIO has been extremely beneficial to us as a small cap public biotech company. In particular, BIO was able to add a revenue requirement for SOX 404(b) qualification. Accordingly, along with our other small cap biotech peers, we will be able to further delay implementing this costly and burdensome regulation."

Marc Belsky
Chief Financial Officer
Kezar Life Sciences

Join BIO Today

Build your network, stay on top of industry topics, advocate for issues critical to your interests, gain access to policymakers, and save money.